Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer
Background: Protein phosphatase 2A (PP2A) is a tumour suppressor frequently inactivated in human cancer and its tyrosine-307 phosphorylation has been reported as a molecular inhibitory mechanism. Methods: Expression of phosphorylated PP2A (p-PP2A) was evaluated in 250 metastatic colorectal cancer (C...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2014-08, Vol.111 (4), p.756-762 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 762 |
|---|---|
| container_issue | 4 |
| container_start_page | 756 |
| container_title | British journal of cancer |
| container_volume | 111 |
| creator | Cristóbal, I Manso, R Rincón, R Caramés, C Zazo, S del Pulgar, T G Cebrián, A Madoz-Gúrpide, J Rojo, F García-Foncillas, J |
| description | Background:
Protein phosphatase 2A (PP2A) is a tumour suppressor frequently inactivated in human cancer and its tyrosine-307 phosphorylation has been reported as a molecular inhibitory mechanism.
Methods:
Expression of phosphorylated PP2A (p-PP2A) was evaluated in 250 metastatic colorectal cancer (CRC) patients. Chi-square, Kaplan–Meier and Cox analyses were used to determine correlations with clinical and molecular parameters and impact on clinical outcomes.
Results:
High p-PP2A levels were found in 17.2% cases and were associated with ECOG performance status (
P
=0.001) and presence of synchronous metastasis at diagnosis (
P
=0.035). This subgroup showed substantially worse overall survival (OS) (median OS, 6.0
vs
26.2 months,
P |
| doi_str_mv | 10.1038/bjc.2014.376 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4134505</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3400651391</sourcerecordid><originalsourceid>FETCH-LOGICAL-c550t-6f2f975739e8f34c1c4d1767558e7cd42fa7268a214f084342e598d17fd5665e3</originalsourceid><addsrcrecordid>eNptkc1v1DAQxS0EokvhxhlZQkgcyOJvO5dKVcWXVAkOcLZcZ9zNksTBdkD973HYpRTEyfLMz2_e-CH0lJItJdy8vtr7LSNUbLlW99CGSs4aapi-jzaEEN2QlpET9Cjnfb22xOiH6IRJQrhSbIO-ftrFPO9iuhlcgQ7PKRboJzz_KrviMmB2jjsokMZ-goznGBOOS_FxBLySrvQwlYx_9GWHR6hPSi157OMQE_jiBuzd5CE9Rg-CGzI8OZ6n6MvbN58v3jeXH999uDi_bLyUpDQqsNBqqXkLJnDhqRcd1UpLaUD7TrDgNFPGMSoCMYILBrI1FQmdVEoCP0VnB915uRqh89VdcoOdUz-6dGOj6-3fnanf2ev43QrKhSSyCrw8CqT4bYFc7NhnD8PgJohLtlRKzqmmilf0-T_oPi5pquutFDO8kqvgqwPlU8w5Qbg1Q4ldU7Q1RbumaGuKFX92d4Fb-HdsFXhxBFz2bgip_m-f_3BGM0YUqVxz4HJtTdeQ7rj73-Cfhua1fA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1552835335</pqid></control><display><type>article</type><title>Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer</title><source>PubMed Central Free</source><source>MEDLINE</source><source>Nature</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Cristóbal, I ; Manso, R ; Rincón, R ; Caramés, C ; Zazo, S ; del Pulgar, T G ; Cebrián, A ; Madoz-Gúrpide, J ; Rojo, F ; García-Foncillas, J</creator><creatorcontrib>Cristóbal, I ; Manso, R ; Rincón, R ; Caramés, C ; Zazo, S ; del Pulgar, T G ; Cebrián, A ; Madoz-Gúrpide, J ; Rojo, F ; García-Foncillas, J</creatorcontrib><description><![CDATA[Background:
Protein phosphatase 2A (PP2A) is a tumour suppressor frequently inactivated in human cancer and its tyrosine-307 phosphorylation has been reported as a molecular inhibitory mechanism.
Methods:
Expression of phosphorylated PP2A (p-PP2A) was evaluated in 250 metastatic colorectal cancer (CRC) patients. Chi-square, Kaplan–Meier and Cox analyses were used to determine correlations with clinical and molecular parameters and impact on clinical outcomes.
Results:
High p-PP2A levels were found in 17.2% cases and were associated with ECOG performance status (
P
=0.001) and presence of synchronous metastasis at diagnosis (
P
=0.035). This subgroup showed substantially worse overall survival (OS) (median OS, 6.0
vs
26.2 months,
P
<0.001) and progression-free survival (PFS) (median PFS, 3.8
vs
13.3 months,
P
<0.001). The prognostic impact of p-PP2A was particularly evident in patients aged <70 years (
P
<0.001). Multivariate analysis revealed that p-PP2A retained its prognostic impact for OS (hazard ratio 2.7; 95% confidence interval, 1.8–4.1;
P
<0.001) and PFS (hazard ratio 3.0; 95% confidence interval, 1.8–5.0;
P
<0.001).
Conclusions:
Phosphorylated PP2A is an alteration that determines poor outcome in metastatic CRC and represents a novel potential therapeutic target in this disease, thus enabling to define a subgroup of patients who could benefit from future treatments based on PP2A activators.]]></description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.2014.376</identifier><identifier>PMID: 25003662</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/53/2422 ; 692/699/67/1504/1885 ; 692/699/67/322 ; Aged ; Alzheimer's disease ; Biological and medical sciences ; Biomarkers, Tumor - metabolism ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Colorectal cancer ; Colorectal Neoplasms - enzymology ; Colorectal Neoplasms - mortality ; Colorectal Neoplasms - pathology ; Confidence intervals ; Drug Resistance ; Epidemiology ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Kaplan-Meier Estimate ; Kinases ; Liver Neoplasms - enzymology ; Liver Neoplasms - mortality ; Liver Neoplasms - secondary ; Male ; Medical prognosis ; Medical sciences ; Metastasis ; Molecular Diagnostics ; Molecular Medicine ; Multiple tumors. Solid tumors. Tumors in childhood (general aspects) ; Multivariate Analysis ; Oncology ; Phosphatase ; Phosphoprotein Phosphatases - metabolism ; Phosphoproteins - metabolism ; Phosphorylation ; Proportional Hazards Models ; Protein Phosphatase 2C ; Protein Processing, Post-Translational ; Proteins ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Tumors</subject><ispartof>British journal of cancer, 2014-08, Vol.111 (4), p.756-762</ispartof><rights>The Author(s) 2014</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Aug 12, 2014</rights><rights>Copyright © 2014 Cancer Research UK 2014 Cancer Research UK</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c550t-6f2f975739e8f34c1c4d1767558e7cd42fa7268a214f084342e598d17fd5665e3</citedby><cites>FETCH-LOGICAL-c550t-6f2f975739e8f34c1c4d1767558e7cd42fa7268a214f084342e598d17fd5665e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134505/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134505/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28722060$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25003662$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cristóbal, I</creatorcontrib><creatorcontrib>Manso, R</creatorcontrib><creatorcontrib>Rincón, R</creatorcontrib><creatorcontrib>Caramés, C</creatorcontrib><creatorcontrib>Zazo, S</creatorcontrib><creatorcontrib>del Pulgar, T G</creatorcontrib><creatorcontrib>Cebrián, A</creatorcontrib><creatorcontrib>Madoz-Gúrpide, J</creatorcontrib><creatorcontrib>Rojo, F</creatorcontrib><creatorcontrib>García-Foncillas, J</creatorcontrib><title>Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description><![CDATA[Background:
Protein phosphatase 2A (PP2A) is a tumour suppressor frequently inactivated in human cancer and its tyrosine-307 phosphorylation has been reported as a molecular inhibitory mechanism.
Methods:
Expression of phosphorylated PP2A (p-PP2A) was evaluated in 250 metastatic colorectal cancer (CRC) patients. Chi-square, Kaplan–Meier and Cox analyses were used to determine correlations with clinical and molecular parameters and impact on clinical outcomes.
Results:
High p-PP2A levels were found in 17.2% cases and were associated with ECOG performance status (
P
=0.001) and presence of synchronous metastasis at diagnosis (
P
=0.035). This subgroup showed substantially worse overall survival (OS) (median OS, 6.0
vs
26.2 months,
P
<0.001) and progression-free survival (PFS) (median PFS, 3.8
vs
13.3 months,
P
<0.001). The prognostic impact of p-PP2A was particularly evident in patients aged <70 years (
P
<0.001). Multivariate analysis revealed that p-PP2A retained its prognostic impact for OS (hazard ratio 2.7; 95% confidence interval, 1.8–4.1;
P
<0.001) and PFS (hazard ratio 3.0; 95% confidence interval, 1.8–5.0;
P
<0.001).
Conclusions:
Phosphorylated PP2A is an alteration that determines poor outcome in metastatic CRC and represents a novel potential therapeutic target in this disease, thus enabling to define a subgroup of patients who could benefit from future treatments based on PP2A activators.]]></description><subject>692/53/2422</subject><subject>692/699/67/1504/1885</subject><subject>692/699/67/322</subject><subject>Aged</subject><subject>Alzheimer's disease</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Colorectal cancer</subject><subject>Colorectal Neoplasms - enzymology</subject><subject>Colorectal Neoplasms - mortality</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Confidence intervals</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Kinases</subject><subject>Liver Neoplasms - enzymology</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - secondary</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical sciences</subject><subject>Metastasis</subject><subject>Molecular Diagnostics</subject><subject>Molecular Medicine</subject><subject>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</subject><subject>Multivariate Analysis</subject><subject>Oncology</subject><subject>Phosphatase</subject><subject>Phosphoprotein Phosphatases - metabolism</subject><subject>Phosphoproteins - metabolism</subject><subject>Phosphorylation</subject><subject>Proportional Hazards Models</subject><subject>Protein Phosphatase 2C</subject><subject>Protein Processing, Post-Translational</subject><subject>Proteins</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNptkc1v1DAQxS0EokvhxhlZQkgcyOJvO5dKVcWXVAkOcLZcZ9zNksTBdkD973HYpRTEyfLMz2_e-CH0lJItJdy8vtr7LSNUbLlW99CGSs4aapi-jzaEEN2QlpET9Cjnfb22xOiH6IRJQrhSbIO-ftrFPO9iuhlcgQ7PKRboJzz_KrviMmB2jjsokMZ-goznGBOOS_FxBLySrvQwlYx_9GWHR6hPSi157OMQE_jiBuzd5CE9Rg-CGzI8OZ6n6MvbN58v3jeXH999uDi_bLyUpDQqsNBqqXkLJnDhqRcd1UpLaUD7TrDgNFPGMSoCMYILBrI1FQmdVEoCP0VnB915uRqh89VdcoOdUz-6dGOj6-3fnanf2ev43QrKhSSyCrw8CqT4bYFc7NhnD8PgJohLtlRKzqmmilf0-T_oPi5pquutFDO8kqvgqwPlU8w5Qbg1Q4ldU7Q1RbumaGuKFX92d4Fb-HdsFXhxBFz2bgip_m-f_3BGM0YUqVxz4HJtTdeQ7rj73-Cfhua1fA</recordid><startdate>20140812</startdate><enddate>20140812</enddate><creator>Cristóbal, I</creator><creator>Manso, R</creator><creator>Rincón, R</creator><creator>Caramés, C</creator><creator>Zazo, S</creator><creator>del Pulgar, T G</creator><creator>Cebrián, A</creator><creator>Madoz-Gúrpide, J</creator><creator>Rojo, F</creator><creator>García-Foncillas, J</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20140812</creationdate><title>Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer</title><author>Cristóbal, I ; Manso, R ; Rincón, R ; Caramés, C ; Zazo, S ; del Pulgar, T G ; Cebrián, A ; Madoz-Gúrpide, J ; Rojo, F ; García-Foncillas, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c550t-6f2f975739e8f34c1c4d1767558e7cd42fa7268a214f084342e598d17fd5665e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>692/53/2422</topic><topic>692/699/67/1504/1885</topic><topic>692/699/67/322</topic><topic>Aged</topic><topic>Alzheimer's disease</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Colorectal cancer</topic><topic>Colorectal Neoplasms - enzymology</topic><topic>Colorectal Neoplasms - mortality</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Confidence intervals</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Kinases</topic><topic>Liver Neoplasms - enzymology</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - secondary</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical sciences</topic><topic>Metastasis</topic><topic>Molecular Diagnostics</topic><topic>Molecular Medicine</topic><topic>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</topic><topic>Multivariate Analysis</topic><topic>Oncology</topic><topic>Phosphatase</topic><topic>Phosphoprotein Phosphatases - metabolism</topic><topic>Phosphoproteins - metabolism</topic><topic>Phosphorylation</topic><topic>Proportional Hazards Models</topic><topic>Protein Phosphatase 2C</topic><topic>Protein Processing, Post-Translational</topic><topic>Proteins</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cristóbal, I</creatorcontrib><creatorcontrib>Manso, R</creatorcontrib><creatorcontrib>Rincón, R</creatorcontrib><creatorcontrib>Caramés, C</creatorcontrib><creatorcontrib>Zazo, S</creatorcontrib><creatorcontrib>del Pulgar, T G</creatorcontrib><creatorcontrib>Cebrián, A</creatorcontrib><creatorcontrib>Madoz-Gúrpide, J</creatorcontrib><creatorcontrib>Rojo, F</creatorcontrib><creatorcontrib>García-Foncillas, J</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cristóbal, I</au><au>Manso, R</au><au>Rincón, R</au><au>Caramés, C</au><au>Zazo, S</au><au>del Pulgar, T G</au><au>Cebrián, A</au><au>Madoz-Gúrpide, J</au><au>Rojo, F</au><au>García-Foncillas, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2014-08-12</date><risdate>2014</risdate><volume>111</volume><issue>4</issue><spage>756</spage><epage>762</epage><pages>756-762</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract><![CDATA[Background:
Protein phosphatase 2A (PP2A) is a tumour suppressor frequently inactivated in human cancer and its tyrosine-307 phosphorylation has been reported as a molecular inhibitory mechanism.
Methods:
Expression of phosphorylated PP2A (p-PP2A) was evaluated in 250 metastatic colorectal cancer (CRC) patients. Chi-square, Kaplan–Meier and Cox analyses were used to determine correlations with clinical and molecular parameters and impact on clinical outcomes.
Results:
High p-PP2A levels were found in 17.2% cases and were associated with ECOG performance status (
P
=0.001) and presence of synchronous metastasis at diagnosis (
P
=0.035). This subgroup showed substantially worse overall survival (OS) (median OS, 6.0
vs
26.2 months,
P
<0.001) and progression-free survival (PFS) (median PFS, 3.8
vs
13.3 months,
P
<0.001). The prognostic impact of p-PP2A was particularly evident in patients aged <70 years (
P
<0.001). Multivariate analysis revealed that p-PP2A retained its prognostic impact for OS (hazard ratio 2.7; 95% confidence interval, 1.8–4.1;
P
<0.001) and PFS (hazard ratio 3.0; 95% confidence interval, 1.8–5.0;
P
<0.001).
Conclusions:
Phosphorylated PP2A is an alteration that determines poor outcome in metastatic CRC and represents a novel potential therapeutic target in this disease, thus enabling to define a subgroup of patients who could benefit from future treatments based on PP2A activators.]]></abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>25003662</pmid><doi>10.1038/bjc.2014.376</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2014-08, Vol.111 (4), p.756-762 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4134505 |
| source | PubMed Central Free; MEDLINE; Nature; EZB-FREE-00999 freely available EZB journals |
| subjects | 692/53/2422 692/699/67/1504/1885 692/699/67/322 Aged Alzheimer's disease Biological and medical sciences Biomarkers, Tumor - metabolism Biomedical and Life Sciences Biomedicine Cancer Research Colorectal cancer Colorectal Neoplasms - enzymology Colorectal Neoplasms - mortality Colorectal Neoplasms - pathology Confidence intervals Drug Resistance Epidemiology Female Gastroenterology. Liver. Pancreas. Abdomen Humans Kaplan-Meier Estimate Kinases Liver Neoplasms - enzymology Liver Neoplasms - mortality Liver Neoplasms - secondary Male Medical prognosis Medical sciences Metastasis Molecular Diagnostics Molecular Medicine Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Multivariate Analysis Oncology Phosphatase Phosphoprotein Phosphatases - metabolism Phosphoproteins - metabolism Phosphorylation Proportional Hazards Models Protein Phosphatase 2C Protein Processing, Post-Translational Proteins Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Tumors |
| title | Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T05%3A21%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phosphorylated%20protein%20phosphatase%202A%20determines%20poor%20outcome%20in%20patients%20with%20metastatic%20colorectal%20cancer&rft.jtitle=British%20journal%20of%20cancer&rft.au=Crist%C3%B3bal,%20I&rft.date=2014-08-12&rft.volume=111&rft.issue=4&rft.spage=756&rft.epage=762&rft.pages=756-762&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.2014.376&rft_dat=%3Cproquest_pubme%3E3400651391%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1552835335&rft_id=info:pmid/25003662&rfr_iscdi=true |